Abstract
To evaluate activity and toxicity of a non platinum-based triplet including Gemcitabine, Ifosfamide and Navelbine (GIN) in advanced NSCLC. Stage IIIB/IV NSCLC patients with WHO PS < 2 and bidimensionally measurable disease entered the study. Gemcitabine 1000 mg/sqm day 1 and 1000–800 mg/sqm day 4, Ifosfamide 3 g/sqm day 1 (with Mesna), Navelbine 25 mg/sqm day 1 and 25–20 mg/sqm day 4 were administered intravenously every 3 weeks. Objective responses (ORs) were evaluated every 2 courses: a maximum of 6 courses were administered in responding patients. According to Simon’s optimal two-stage design more than 18 ORs out of 54 patients were required to establish the activity of this regimen. Fifty patients entered the study. Main characteristics of the 48 evaluated patients were: median age 63 years, ECOG performance status 0 = 65%, stage IV disease 79% and non-squamous histology 71%. The total number of courses administered was 200, median per patient 4 (range 1–6). Toxicities were evaluated according to WHO criteria: neutropenia grade 3–4 occurred in 47% of the courses; thrombocytopenia grade 3–4 in 6.6%; anaemia grade 3 in 3.5%. Twelve episodes of febrile neutropenia were reported and three patients required hospital admission. No toxic death was reported. Non-haematological toxicity, including skin rash, alopecia and fatigue, were generally. Twenty-five ORs (1 complete response and 24 partial responses) were obtained for a response rate of 52% (95% CI: 37.4–66.5%). One-year survival was 46.5%. This non-platinum-based outpatient triplet showed promising activity against NSCLC with myelosuppression, in particular neutropenia, being dose-limiting. The GIN regimen may represent a valuable alternative to standard platinum-based doublets and triplets in the treatment of advanced NSCLC and further studies with this platinum-free combination are warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baldini E, Tibaldi C, Chella A, Angeletti CA, Silvano G, Andrei A, Algeria R and Conte PF (1996) Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. Ann Oncol 7: 747–749
Baldini E, Silvano G, Tibaldi C, Campoccia S, Cionini L and Conte PF (2000) Sequential chemoradiation therapy with vinorelbine, ifosfamide and cisplatin in stage IIIB non-small-cell lung cancer: A phase II study. Semin Oncol 27, (Suppl 1):28–32
Boni L, Pennucci MC and Ardizzoni A et al (1997) Factors affecting response rate (RR) and survival (OS) in advanced non-small-cell lung cancer (NSCLC): retrospective analysis on 1128 patients. Lung Cancer 18, (Suppl 1):5
Bonomi P, Kyungmann K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M and Johnson D (2000) Comparison of survival and quality of life in advanced NSCLC patients treated with two dose-levels of paclitaxel combined with cisplatin vs etoposide with cisplatin: an Eastern Cooperative Oncology Group (ECOG) trial. J Clin Oncol 18: 623–631
Comella P, Frasci G, Panza N, Manzione L, Lorusso V, Di Rienzo G, Cioffi R, De Cataldio G, Maiorino L, Bilancia D, Natale M, Carpagnano F, Pacilio C, De Lena M, Bianco A and Comella G (1999) Cisplatin, gemcitabine and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 17: 1526–1534
Comella P, Frasci G, Panza N, Manzione L, De Cataldo G, Cioffi R, Maiorino L, Micillo E, Lorusso V, DiRienzo G, Filippelli G, Lamberti A, Natale M, Bilancia D, Nicolella G, Di Nota A and Comella G (2000) Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase II trial of the Southern Italy Cooperative Group. J Clin Oncol 18: 1451–1457
Crawford J (1996) Vinorelbine in the treatment of non-small-cell lung cancer. Semin Oncol 23, (Suppl 5):2–8
Crinò L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C, Meacci M, Corgna E, Darwish S, Scarcella L, Santucci A, Ballatori E and Tonato M (1995) Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens: A randomised trial of the Italian Oncology Group for Clinical trial research (GOIRC). Ann Oncol 6: 347–353
Crinò L, Scagliotti G, Marangolo M, De Marinis F, Rinaldi M, Gridelli C, Ciribelli A, Bianco R, Marangolo M, Di costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone C, Cruciani G, Masotti A, Ferrarar G, Gozzellino F and Tonato M (1997) Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15: 297–303
Crinò L, Scagliotti GV and Ricci S et al (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522–3530
Eberhardt W and Niederle N (1992) Ifosfamide in non-small cell lung cancer: a review. Semin Oncol 19, (Suppl 1):40–48
Frasci G, Panza N and Manzione L (2000) Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Group. J Clin Oncol 18: 1451–1457
Georgoulias V, Papadakis E, Alexopulos A, Tsiafakis X, Rapti A, Veslemes M, Palamidas P and Vlachonikos I (2000) Docetaxel plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial. Proc 10th International Congress on Anticancer Treatment, (abstr 14),82–83
Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmond T and Postmus PE (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European organization for Research and Treatment of Lung Cancer Cooperative Group. J Clin Oncol 16: 2133–2141
Gralla RJ, Rittenberg CN, Silverman CB, Maeques CB, Maulick JF and Cole JT (1998) Gemcitabine + vinorelbine in combination with mitomycin in non-small-cell lung cancer (NSCLC): results of a phase I and phase II study of an active outpatient regimen. Proc Am Soc Clin Oncol 17: 486(abstr 1871)
Gridelli C, Frontini L, Perrone F, Gallo C, Gulisano M, Cigolari S, Castiglione F, Robbiati SF, Gasparini G, Iannello GP, Farris A, Locatelli MC, Felletti R and Piazza E (2000) Gemcitabine plus vinorelbine in advanced non-small-cell lung cancer: a phase II study of three different doses. Br J Cancer 83: 707–714
Kaplan EL and Meier P (1998) Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457–481
Loprevite M, Favoni RE, De Cupis A, Pirani P, Merlo F, Grosssi F and Ardizzoni A (1999) Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity. Int J Oncol 15: 787–792
Miller AB, Hoogstraaten B and Staquest M (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Morere F, Piperno S, Brunet A, Boaziz C, Khon M, Bouillet T and Breau JL (1997) Vinorelbine and ifosfamide for unresectable non-small-cell lung cancer. Lung Cancer 18: 95–100
Pirker R, Krajnik G, Zochbauer S, Malayeri R, Kneusssl M and Huber H (1995) Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 6: 833–835
Sculier JP, Klastersky J, Giner V, Bureau G, Thiriaux J, Dabouis G, Efremidis A, Ries F, Berchier MC and Sergysels R (1994) Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 12: 353–359
Sheperd FA (1995) Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small-cell lung cancer: an overview. Anticancer Drug 6: 19–25
Simon R (1989) Optimal two-stage design for phase II clinical trials. Controlled Clin Trials 10: 1–10
Stewart LA and Pignon JP (1995) Chemotherapy in non-small cell lung cancer. A meta-analysis using updated individual patients data from 52 randomized clinical trials. BMJ 311: 899–909
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Baldini, E., Ardizzoni, A., Prochilo, T. et al. Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC). Br J Cancer 85, 1452–1455 (2001). https://doi.org/10.1054/bjoc.2001.2108
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.2108
Keywords
This article is cited by
-
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
British Journal of Cancer (2012)
-
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study
Cancer Chemotherapy and Pharmacology (2008)
-
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)
British Journal of Cancer (2003)
